New Kits Speed iPSC Differentiation for Research

Amsbio has expanded its range of iPSC Differentiation Kits that provide fast and flexible generation of specific cell types without sacrificing cell purity.

New to market - Quick-Glia™ product line consist of human induced pluripotent stem cell derived glial cells designed for rapid, reliable, and reproducible research in neurobiology, drug discovery, and neurodegeneration. Offering a reproducible, and scalable solution, these kits enable the conversion of iPSCs into functional neurons in just 1-2 weeks. Designed for ease of use, they provide a streamlined workflow for disease modelling, drug screening, and neurobiology applications.

Quick-Glia™ Astrocyte – SeV kits facilitate the differentiation of human pluripotent stem cells into astrocytes using Sendai virus technology through a streamlined and reproducible workflow. These new easy-to-use kits offer rapid differentiation to reproducibly produce highly pure populations of astrocyte cells. Neuroscience researchers are intensely interested in astrocytes because they are now recognized as active, dynamic regulators of brain function. Characterization of iPSC-derived astrocytes is crucial to ensure their utility in research. Employing astrocyte markers, researchers can confirm the identity and purity of these cells.

There are also Quick-Glia™ human iPSC-derived microglia. These are high purity, off-the-shelf microglia that provide a consistent, biologically relevant in vitro model for studying human microglial biology and disease. These cryopreserved, ready-to-use iPSC-derived microglia mature rapidly and deliver reproducible performance for drug discovery, toxicity screening, and neurodegenerative disease research. The associated microglia maintenance media is also available and offered separately.

This article has been republished from external sources. Note: Material may have been edited for clarity, length, or style. For more information, please contact the cited source.